Related Experiment Video
Updated: Jun 6, 2026

Probiotic Studies in Neonatal Mice Using Gavage
Published on: January 27, 2019
Lactobacillus GG treatment during pregnancy for the prevention of eczema: a randomized controlled trial
R J Boyle1, I H Ismail, S Kivivuori
1Allergy and Immune Disorders, Murdoch Children's Research Institute, University of Melbourne, Melbourne, Australia.
Insights
Prenatal probiotic supplementation with Lactobacillus rhamnosus GG did not prevent eczema in infants. Further research into postnatal probiotic use or alternative strains is needed for eczema prevention.
Area of Science:
- Immunology
- Microbiology
- Pediatrics
Background:
- Early-life probiotic supplementation shows promise for eczema prevention.
- Prenatal probiotic administration is hypothesized to be particularly effective.
Purpose of the Study:
- To investigate if prenatal treatment with Lactobacillus rhamnosus GG (LGG) impacts infant eczema risk.
- To assess the influence of prenatal LGG on allergic sensitization and immune markers.
Main Methods:
- A randomized controlled trial involving 250 pregnant women receiving LGG or placebo from 36 weeks gestation.
- Infant eczema and sensitization were monitored during the first year.
- Immunological assessments included cord blood cytokine profiles and breast milk immune factors.
Main Results:
- Prenatal LGG did not significantly reduce the risk of eczema or IgE-associated eczema.
- No significant changes were observed in cord blood immune markers.
- A decrease in breast milk soluble CD14 and IgA levels was noted with prenatal probiotic treatment.
Conclusions:
- Prenatal Lactobacillus rhamnosus GG supplementation alone is insufficient for preventing infant eczema.
- Effective probiotic strategies for eczema prevention may require postnatal administration or different bacterial strains.
Background:
Probiotic supplementation in early life may be effective for preventing eczema. Previous studies have suggested that prenatal administration may be particularly important for beneficial effects.
Objective:
We examined whether prenatal treatment with the probiotic Lactobacillus rhamnosus GG (LGG) can influence the risk of eczema during infancy.
Methods:
We recruited 250 pregnant women carrying infants at high risk of allergic disease to a randomized controlled trial of probiotic supplementation (LGG 1.8 × 10(10) cfu/day) from 36 weeks gestation until delivery. Infants were assessed during their first year for eczema or allergic sensitization. Immunological investigations were performed in a subgroup. Umbilical cord blood was examined for dendritic cell and regulatory T cell numbers and production of TGFβ, IL-10, IL-12, IL-13, IFN-γ and TNFα. Maternal breast milk was examined for total IgA, soluble CD14 and TGFβ.
Results:
Prenatal probiotic treatment was not associated with reduced risk of eczema (34% probiotic, 39% placebo; RR 0.88; 95% CI 0.63, 1.22) or IgE-associated eczema (18% probiotic, 19% placebo; RR 0.94; 95% CI 0.53, 1.68). Prenatal probiotic treatment was not associated with any change in cord blood immune markers, but was associated with decreased breast milk soluble CD14 and IgA levels.
Conclusions:
Prenatal treatment with Lactobacillus rhamnosus GG was not sufficient for preventing eczema. If probiotics are effective for preventing eczema, then a postnatal component to treatment or possibly an alternative probiotic strain is necessary.
Related Concept Videos
Microbiota Modulation by Antibiotics
Development of Human Microbiota
Acne Infection
Development of the Oral Microbiota
Transcytosis of IgG
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
Probiotics
